Format
Sort by

Send to

Choose Destination

Search results

Items: 15

1.

[Lipids and the size of lipoprotein particles in newly diagnosed and untreated patients with type 2 diabetes mellitus].

Dukát A, Fábryová L, Oravec S, Sabaka P, Mistríková L, Baláž D, Gavornik P, Gašpar L.

Vnitr Lek. 2013 Jun;59(6):450-2. Czech.

PMID:
23808737
2.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

3.

[Past, present and future of obesity pharmacotherapy].

Fábryová L.

Vnitr Lek. 2010 Oct;56(10):1058-64. Review. Slovak.

PMID:
21105452
4.

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group.

Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8. Erratum in: Lancet. 2010 Jul 24;376(9737):234.

PMID:
20417856
5.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team.

Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.

PMID:
19501900
6.

Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity?

Gasparovic J, Basistová Z, Fábryová L, Wsólová L, Vohnout B, Raslová K; Slovak MED PED FH group.

Atherosclerosis. 2007 Oct;194(2):e95-107. Epub 2006 Dec 27.

PMID:
17194460
7.

Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B-100: the MEDPED Slovakia Project.

Vohnout B, Raslová K, Gasparovic J, Franeková J, Fábryová L, Belosovicová M, Kovác G, Sebová C, Rajecová E, Stavný J, Babjak M, Donati MB, Iacoviello L.

Atheroscler Suppl. 2003 Nov;4(3):3-5.

PMID:
14615272
8.
9.

[Free oxygen radicals in atherosclerosis and diabetes mellitus].

Fábryová L, Cagán S.

Bratisl Lek Listy. 1995 Jan;96(1):23-9. Slovak.

PMID:
7633906
10.

[Haemotherapy and antibodies anti-hl-a (author's transl)].

Drobná V, Gazová S, Fábryová L, Hrubisko M.

Bratisl Lek Listy. 1975 Jul;64(1):81-5. Slovak. No abstract available.

PMID:
1156893
11.

[RHnull disease].

Hrubisko M, Fábryová L, Lipsic T.

Vnitr Lek. 1974 Jul;20(6):555-62. Slovak. No abstract available.

PMID:
4210818
12.

[Therapeutic modification of polycythemia vera by transferred anti-erythrocyte antibodies].

Hrubisko M, Fábryová L, Lipsic T.

Haematologia (Budap). 1973;7(1):25-33. German. No abstract available.

PMID:
4146768
13.

[Vercyte in the therapy of polycythemia].

Fábryová L, Hrubisko M.

Vnitr Lek. 1972 Nov;18(11):1113-6. Slovak. No abstract available.

PMID:
4634660
14.

[Trial to influence polycythemia with erythrocyte-antibodies. I. Preliminary clinical results].

Hrubisko M, Fãbryovã L, Lipsic T.

Vnitr Lek. 1971 Sep;17(9):879-87. Slovak. No abstract available.

PMID:
5129135
15.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk